Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
83.84(c) 84.29(c) 85.18(c) 85.93(c) 85.72(c) Last
5 401 937 4 534 174 5 505 490 7 018 372 14 073 291 Volume
+0.62% +0.54% +1.06% +0.88% -0.24% Change
More quotes
Financials (USD)
Sales 2021 51 668 M - -
Net income 2021 9 938 M - -
Net Debt 2021 22 978 M - -
P/E ratio 2021 20,7x
Yield 2021 3,53%
Sales 2022 53 872 M - -
Net income 2022 10 930 M - -
Net Debt 2022 17 542 M - -
P/E ratio 2022 18,8x
Yield 2022 3,64%
Capitalization 208 B 209 B -
EV / Sales 2021 4,48x
EV / Sales 2022 4,19x
Nbr of Employees 110 000
Free-Float 87,4%
More Financials
Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and... 
Read more
Sector
Pharmaceuticals
Calendar
06/22 | 08:30amSpecial Situation
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVARTIS AG
06/18NOVARTIS  : Study Shows Improved Motor Function in Children with Spinal Muscular..
MT
06/18PRESS RELEASE  : Novartis: New Zolgensma data -3-
DJ
06/18PRESS RELEASE  : Novartis: New Zolgensma data -2-
DJ
06/18PRESS RELEASE  : Novartis: New Zolgensma data demonstrate age-appropriate develo..
DJ
06/18NOVARTIS  : New Zolgensma data demonstrate age-appropriate development when used..
DJ
06/18CureVac Could Allow Manufacturing Partners To Produce Rival Vaccines
MT
06/17NOVARTIS INDIA  : Consolidated Net Profit Climbs in Fiscal Q4
MT
06/17CureVac may let contractors make rival vaccines if own shot fails -CEO
RE
06/17CureVac may let contractors make rival vaccines if own shot fails - CEO
RE
06/17NOVARTIS AG  : Deutsche Bank keeps its Buy rating
MD
06/17EMEA MORNING BRIEFING  : Fed's Surprise Hawkish -2-
DJ
06/16NOVARTIS  : Wins US FDA Breakthrough Therapy Designation For Prostate Cancer Tre..
MT
06/16CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
RE
06/16NOVARTIS  : prostate cancer drug receives U.S. FDA breakthrough designation
RE
06/16NOVARTIS  : AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains A..
MT
More news
News in other languages on NOVARTIS AG
06/18NOVARTIS : résultats positifs pour Zolgensma chez les enfants atteints de SMA
06/18Novartis mit positiven Studiendaten zu Zolgensma
06/18Aktien Schweiz: SMI bleibt zum Hexensabbat auf Rekordkurs
06/18Bourse Zurich: charmé par les "quatre sorcières", le SMI tient les 12'000 poi..
06/18Aktien Schweiz Eröffnung: SMI bleibt zum Hexensabbat auf Rekordkurs
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Analysis
Novartis : to close Swiss plant, 50 jobs to go
Stock Pick
 NOVARTIS AG
Back to basics
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 106,54 $
Last Close Price 92,83 $
Spread / Highest target 60,4%
Spread / Average Target 14,8%
Spread / Lowest Target -5,68%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.47%208 642
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
ABBVIE INC.5.57%199 795
ELI LILLY AND COMPANY29.44%198 668